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Genome- wide single nucleotide polymorphism- based 
autozygosity mapping facilitates identification of mutations in 
consanguineous families with epidermolysis bullosa
Abstract
Autozygosity mapping (AM) is a technique utilised for mapping ho-
mozygous autosomal recessive (AR) traits and facilitation of genetic 
diagnosis. We investigated the utility of AM for the molecular diag-
nosis of heterogeneous AR disorders, using epidermolysis bullosa (EB) 
as a paradigm. We applied this technique to a cohort of 46 distinct 
EB families using both short tandem repeat (STR) and genome- wide 
single nucleotide polymorphism (SNP) array- based AM to guide tar-
geted Sanger sequencing of EB candidate genes. Initially, 39 of the 46 
cases were diagnosed with homozygous mutations using this method. 
Independently, 26 cases, including the seven initially unresolved 
cases, were analysed with an EB- targeted next- generation sequencing 
(NGS) panel. NGS identified mutations in five additional cases, initially 
undiagnosed due to the presence of compound heterozygosity, deep 
intronic mutations or runs of homozygosity below the set threshold of 
2 Mb, for a total yield of 44 of 46 cases (95.7%) diagnosed genetically.
1  | BACKGROUND
The diagnosis of heritable disorders, particularly genodermatoses, 
is complicated by genetic, phenotypic and clinical heterogeneity. 
Routine genetic diagnosis was originally based on PCR amplification 
and sequencing of exons and flanking introns in candidate genes 
identified by prescreening tools, in addition to clinical presentation. 
More recently, next- generation sequencing (NGS) methods, such as 
targeted panels and whole- exome/genome sequencing, have been 
incorporated into the diagnosis of these disorders.
A number of screening methods, taking advantage of the extensive 
polymorphism of the human genome, have been shown to facilitate 
the identification of candidate genes.[1] Autozygosity mapping (AM), 
initially based on restriction fragment length polymorphisms or short 
tandem repeat (STR) microsatellite markers, has been used to map 
recessive traits in consanguineous families.[2,3] While STRs are highly 
polymorphic, with up to 30 distinct alleles for each STR,[4] they are not 
amenable for high- throughput analysis. The advent of high- density 
single nucleotide polymorphism (SNP) arrays has allowed genome- 
wide mapping of regions of homozygosity (ROH) at high resolution for 
a relatively low cost in consanguineous and outbred (eg in the case of 
a founder effect) families.[1,5,6] AM can be used alone for mapping of 
causative genes before mutation analysis by Sanger sequencing or in 
combination with NGS to improve the mutation detection rate.
Epidermolysis bullosa (EB), the paradigm of skin fragility disor-
ders, is caused by mutations in as many as 20 genes, most of which 
cause disease in a biallelic manner.[7-9] While EB can be classified into 
the subtypes of EB simplex (EBS), junctional EB (JEB), dystrophic EB 
(DEB) and Kindler syndrome (KS) based on the layer of cutaneous blis-
tering, there is significant phenotypic variability within this group of 
disorders,[7] especially in early life. Given the heterogeneity of EB, it 
serves as a model disease to assess the functionality of AM in facilitat-
ing genetic diagnosis. We applied STR and whole- genome SNP- based 
AM in 46 families (Families 1- 46) with EB with a consanguineous 
background from Iran, a country in which 39% of marriages are con-
sanguineous.[10] To provide a full investigation of the merits of AM in 
our cohort of EB patients, this study reports on a combination of pre-
viously unreported patients in our cohort and previous results.[11-13]
2  | QUESTIONS ADDRESSED
We investigated the clinical utility of AM for the molecular diagnosis 
of Mendelian disorders with extensive genetic heterogeneity in a co-
hort affected by EB with a high degree of consanguinity.
3  | EXPERIMENTAL DESIGN
See Data S1 for complete materials and methods.
4  | RESULTS
Following STR and SNP- based AM, alignment of EB- related genes 
with ROH in combination with clinical correlation identified putative 
candidate gene(s) in 43 of 46 families (Table 1, Table S1). Subsequent 
sequencing of the suggested gene(s) identified causative homozygous 
Abbreviations: AM, autozygosity mapping; AR, autosomal recessive; DEB, dystrophic EB; EB, epidermolysis bullosa; EBS, EB simplex; JEB, junctional EB; KS, Kindler syndrome; NGS, next-gener-
ation sequencing; RDEB, recessive DEB; ROH, run of homozygosity; SNP, single nucleotide polymorphism; STR, short tandem repeat.
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mutations in 39 families (84.7%). In the remaining families, sequenc-
ing of exon 1 in KLHL24 failed to identify mutations in this recently 
described candidate gene.[8] The pathogenicity of missense mutations 
revealed in this study was determined by bioinformatics prediction 
programmes (Table S2).
As an example, Family 7 was referred with an initial diagnosis of 
laryngo- onycho- cutaneous (LOC, Shabbir) syndrome, usually caused by 
mutations in LAMA3A.[14] However, sequencing of LAMA3 in another 
laboratory was unyielding. Sanger sequencing guided by SNP- based 
AM revealed a novel homozygous mutation in LAMB3:c.3163delG 
(Figure 1). Additional examples of this successful diagnostic approach 
are shown in Figures S1 and S2.
Seven unresolved cases of 46 remained. In three of these families 
(Families 4, 11 and 35), no ROH for EB- associated genes was identi-
fied. In four other families (Families 21, 23, 32 and 42), initial sequenc-
ing failed to identify a causative variant despite the identification of 
candidate genes using ROH. There are several factors contributing to 
the lack of initial identification of mutations, which call attention to 
potential pitfalls of AM.
First, the parameters utilised to overlap ROH with candidate 
genes can affect the detection rate. For example, in Families 11 
and 35, no candidate genes were initially identified in ROH ≥2 Mb. 
However, eventual NGS identified a homozygous deletion in 
COL7A1 and a homozygous nonsense mutation in LAMB3, respec-
tively. Further analysis revealed that these mutations reside within 
ROH of less than 2 Mb.
Second, there were two cases (Families 4 and 32) in which AM 
with subsequent sequencing failed to identify a causative mutation 
due to the presence of a compound heterozygous mutation, raising 
the issue that, while extremely rare in highly consanguineous pop-
ulations, compound heterozygosity can lead to misleading findings.
The lack of genetic diagnosis in the three remaining cases was 
likely due to a combination of factors. In Family 23, two affected sib-
lings with nephrotic syndrome, interstitial lung disease and skin fragil-
ity were found to have a single overlapping ROH of 12 Mb harbouring 
ITGA3. While this gene has been associated with this phenotype of 
kidney, lung and skin disease,[15] subsequent NGS failed to identify 
mutations within exons or the exon- intron junctions. This suggests 
that probably there is a deep intronic mutation affecting ITGA3 ex-
pression in this family, and RNA sequencing can further delineate 
the molecular pathology in this case. In Family 42, NGS identified 
a causative homozygous nonsense mutation in PLEC (p.Arg2424*). 
PLEC was not present in our STR library and thus was not identified 
as a candidate gene in this case. In Family 21, a case of lethal neona-
tal EB, while COL17A1 was suggested by AM, subsequent NGS was 
unyielding.
Of note, the yield of 84.7% using AM- guided sequencing was re-
markably similar to that of the independent use of our previously re-
ported NGS- targeted panel,[12] in which potential causative variants 
were identified in 76 of 91 (83.5%) families with EB, the AM approach 
being expedient and cost- efficient in case of consanguinity in the fam-
ilies. Additionally, combining AM with targeted NGS panels has signifi-
cantly improved our mutation detection rate. Use of AM can narrow 
down the list of potential variants from an NGS panel and can provide 
additional evidence for the causative role of variants of unknown sig-
nificance, such as missense and intronic variants. Finally, it should be 
noted that NGS data can be used to generate SNP- based homozygosity 
maps.
TABLE  1 Summary of genetic findings in EB cohort using 
autozygosity mapping (AM) followed by sequencing of candidate 
gene(s)
Total cases 46
Candidate gene(s) identified by AM 43
No candidate gene identified 3
Homozygous mutation identified 39
EB simplex—AR 5
Junctional EB 18
Recessive dystrophic EB 15
Kindler syndrome 1
Novel variants 8
No initial mutation identified 7
Compound heterozygous 2
Mutation in <2 Mb block 2
Not targeted by STR mapping 1
Unknown 2
AM, autozygosity mapping; EB, epidermolysis bullosa; AR, autosomal re-
cessive; STR, short tandem repeat.
F IGURE  1 Autozygosity mapping, representative clinical 
features, immunoepitope mapping and mutation analysis of the 
candidate gene in a case of laryngo- onycho- cutaneous syndrome. A 
SNP panel of 550 000 markers was used to identify homozygosity 
blocks of ≥2 Mb (vertical blue lines) along the entire autosome; 
chromosomes 1- 22 are listed at the bottom. The genomic loci of 
candidate genes known to be associated with EB are indicated by 
vertical dotted lines as shown in the panel. Pedigree of a first cousin 
consanguineous marriage with autosomal recessive inheritance 
pattern and homozygosity mapping in the proband of Family 7, 
who was initially diagnosed with laryngo- onycho- cutaneous (LOC; 
Shabbir) syndrome. Note the cutaneous erosions and excess 
granulation tissue on the chin and nasal cavity as well as dystrophic 
changes in the nails. Only one EB- related gene co- aligned with a 
homozygosity block, implicating LAMB3 on chromosome 1q32.2 
(yellow box). Staining with a monoclonal antibody against integrin 
ß4 (MAB 1964, Millipore Co., Billerica, MA, USA) marked the blister 
roof (left) and with a monoclonal antibody against collagen VII (MAB 
1345, Millipore Co.) marked the blister floor (right); localisation of 
these two proteins in immunofluorescence analysis indicated that the 
level of cleavage is within lamina lucida suggesting the diagnosis of 
JEB. Sanger sequencing analysis revealed the mutation c.3163delG 
(p.Ala1055Glnfs*17) in the LAMB3 gene
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5  | CONCLUSIONS
The use of AM in Mendelian disorders with extensive genetic hetero-
geneity in consanguineous populations is a highly effective method 
for mutation detection, comparable to a multigene NGS panel for EB. 
We propose that AM can have a similar efficacy for other heterogene-
ous disorders with autosomal recessive inheritance, in isolation or in 
combination with NGS techniques.
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